Liminatus Pharma Inc (NASDAQ:LIMN) shares, rose in value on Friday, June 20, with the stock price up by 12.73% to the previous day’s close as strong demand from buyers drove the stock to $14.43.
Actively observing the price movement in the last trading, the stock closed the session at $12.80, falling within a range of $12.87 and $16.13. The value of beta (5-year monthly) was 0.17. Referring to stock’s 52-week performance, its high was $26.68, and the low was $4.40. On the whole, LIMN has fluctuated by 129.05% over the past month.
With the market capitalization of Liminatus Pharma Inc currently standing at about $375.39 million, investors are eagerly awaiting this quarter’s results, scheduled for in July.
The stock’s technical analysis shows that the price of LIMN currently trading nearly 15.45% and 46.62% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 52.88, while the 7-day volatility ratio is showing 12.65% which for the 30-day chart, stands at 34.54%. Furthermore, Liminatus Pharma Inc (LIMN)’s beta value is 0.21, and its average true range (ATR) is 3.91.
A comparison of Liminatus Pharma Inc (LIMN) with its peers suggests the former has fared considerably weaker in the market. LIMN showed an intraday change of 12.73% in last session, and over the past year, it grew by 41.47%%.
Data on historical trading for Liminatus Pharma Inc (NASDAQ:LIMN) indicates that the trading volumes over the past 10 days have averaged 0.55 and over the past 3 months, they’ve averaged 281.46K. According to company’s latest data on outstanding shares, there are 26.01 million shares outstanding.
Nearly 23.72% of Liminatus Pharma Inc’s shares belong to company insiders and institutional investors own 1.75% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 9549.0 shares as on 2025-05-30, resulting in a short ratio of 0.12. The stock has risen by 28.61% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the LIMN stock heading into the next quarter.
